“FDAs recent critical path initiative has focused on the challenges involved in the development of new innovator drugs, devices, and biologics. Some of the focus areas identified, such as manufacturing science, apply equally to the development of generic drugs. However, there are scientific challenges unique to the development of generic drugs. The purpose of this document is to bring these challenges to the attention of interested parties and identify opportunities for collaborative solutions.”
Sorry, comments are closed for this post.